Our Mission
Rebuild Cells Rescue Lives
Our Vision
Make Miracles Happen Make Miracles Often
Our Values
Concentration，Innovation，Inclusion，Collaboration
About Us
Founded in 2019, Juncell Therapeutics has been hailed as a "unicorn company" for developing innovative TIL therapies in the field of solid tumor treatment. As a national high-tech enterprise and one of "Shanghai Specialized and Innovative Enterprises", we are currently at the stage of clinical research. In addition, we won the highest award "Excellence Award" in the "National Disruptive Technology Innovation Competition" organized by the Ministry of Science and Technology of China, and was selected as a candidate for disruptive technology in MOST's database.
Juncell Therapeutics has established a facility platform covering 3,000m2 R&D headquarters, with a supporting quality management system, and over 16,000㎡ intelligent TIL manufacturing facility. By virtue of the innovative DeepTIL® cell expansion platform and the NovaGMP® gene modification platform, our company has developed a series of natural TIL and non-viral vector-based genetically modified TIL therapies, among which, 2 piplines are in clinical trials.
Core Technology
-
DeepTIL®cell expansion platform
☛ Highly efficient TIL enrichment for all tumor types
Clinical-grade TILs can be obtained with a high successful rate ＞90%.
☛ Simplified process without feeder cells
The expansion of TILs becomes easier and cheaper with no healthy human PBMCs.
☛ No lymphodepletion pre-treatment or IL-2 injections
Patients can receive treatment just in general wards.
-
NovaGMP®gene modification platform
☛ Safer
No risk of wild-type virus mutaions.
☛ Cheaper
The non-viral vector-based gene modification costs less than 1/10 of the viral vectors system.
☛ More efficient
TILs have stronger anti-tumor activity and in vivo adaptation capability with transfection efficiency ＞45% .
-
RobustThe same process；High successful cultivation rate＞95%
-
CompetentBillion level cells；Specific T cells＞60%
-
AffordableFeeder cells-free；Non-viral vector at a low cost
-
AccessibleLess intensive pretreatment；IL-2 injection-free
Clinical Trials
-
A Phase II Trial of GC101 TIL in Advanced MelanomaBeijing Cancer Hospital, Fujian Cancer Hospital, Fudan University Shanghai Cancer Center, Zhejiang Cancer hospital, Hunan Cancer Hospital, Henan Cancer Hospital, Cancer Hospital of Shandong First Medical University, etc.. -
A Phase Ib Trail of GC101 TIL in NSCLCShanghai Chest Hospital, Anhui Chest hospital, Hunan Cancer Hospital -
A Phase I Trial of GC203 TIL in Advanced Malignant Solid TumorsFudan University Shanghai Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tenth People’s hospital of Tongji University, The Second Affiliated Hospital Zhejiang University School of Medicine, etc. -
A Phase I Trial of GC101 TIL in Advanced Malignant Solid TumorsChinese PLA General Hospital
News
Partners
